STOCK TITAN

Alector to Host Mid-Year Earnings Conference Call

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
Alector, Inc. will host a conference call and webcast on August 3, 2023, to discuss second quarter results and provide a mid-year business update.
Positive
  • Investors can gain insights into Alector's performance and future plans during the conference call and webcast.
Negative
  • None.

Call Scheduled for Thursday, August 3, 2023, at 4:30 p.m. ET/1:30 p.m. PT

SOUTH SAN FRANCISCO, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced it will host a conference call and webcast on Thursday, August 3, 2023, at 4:30 p.m. ET to discuss results for the second quarter ended June 30, 2023, and provide a mid-year business update. A press release detailing second quarter results will be issued prior to the call.

The event will be webcast live under the investor relations section of Alector’s website at https://investors.alector.com/events-and-presentations/events and following the event a replay will be archived there for 30 days. Interested parties participating by phone will need to register using this online form. After registering for dial-in details, all phone participants will receive an auto-generated e-mail containing a link to the dial-in number along with a personal PIN number to use to access the event by phone.

About Alector
Alector is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector has discovered and is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable rejuvenated immune cells to counteract emerging brain pathologies. Alector’s immuno-neurology product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer’s disease. Alector is headquartered in South San Francisco, California. For additional information, please visit www.alector.com.

Alector Contacts:

Alector
Katie Hogan
202-549-0557
katie.hogan@alector.com

1AB (media)
Dan Budwick
973-271-6085
dan@1abmedia.com

Argot Partners (investors)
Laura Perry
212.600.1902
alector@argotpartners.com


FAQ

When is Alector's conference call and webcast scheduled?

Alector's conference call and webcast is scheduled for August 3, 2023.

What will be discussed during the conference call and webcast?

The conference call and webcast will cover the second quarter results and provide a mid-year business update.

Where can I access the webcast?

The webcast can be accessed on Alector's website under the investor relations section.

Will there be a replay of the webcast available?

Yes, a replay of the webcast will be archived on Alector's website for 30 days.

Alector, Inc.

NASDAQ:ALEC

ALEC Rankings

ALEC Latest News

ALEC Stock Data

506.98M
75.76M
9.93%
79.61%
6.76%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
SOUTH SAN FRANCISCO

About ALEC

we are a biotech company based in san francisco dedicated to the discovery and development of novel therapies harnessing the power of immune system to treat neurodegenerative diseases such as alzheimer's disease.